[ad_1]
Cytonus Therapeutics Inc. (Cytonus), a biotechnology company developing therapeutic products for targeted delivery in vivoannounces that their CSO, Dr. Richard Klemke Ph.D., will present the preclinical progress made on Cytonus’ lead Cargocyte product candidates at the annual AACR meeting in New Orleans.
Cargocytes armed with interleukin 12 (CA-IL-12) can be engineered to actively home, migrate, and penetrate deep into specific disease foci and synthesize biologically active therapeutic within the target tissues, hours after intravenous administration.
Dr. Klemke will share data demonstrating striking infiltration of engineered Cargocytes into solid tumors in in vivo models of metastatic Triple Negative Breast Cancer (TNBC), localizing and synthesizing the company’s proprietary Interleukin twelve (IL-12) construct. Furthermore, Dr. Klemke will share in vivo data demonstrating the efficacy of tumor-localized activity of CA-IL-12 in reducing tumor burden, particularly in combination with immune checkpoint inhibitors.
Abstract #3519: Bioengineering enucleated cell vehicles for targeted delivery of Interleukin 12 to metastatic tumors.
|
Session: Immunomodulatory Agents and Interventions 2, on 4/12/2022. |
|
|
Session Start Time: |
1:30:00pm |
|
Session End Time: |
5:00:00 PM |
Full story available on Benzinga.com
[ad_2]
Source link
